Park Place Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-4
Closed -$2.09K – 583
2026
Q1
$2.09K Hold
4
– – ﹤0.01% 752
2025
Q4
$2.33K Hold
4
– – ﹤0.01% 702
2025
Q3
$1.84K Hold
4
– – ﹤0.01% 715
2025
Q2
$1.2K Hold
4
– – ﹤0.01% 770
2025
Q1
$1.32K Hold
4
– – ﹤0.01% 764
2024
Q4
$1.23K Hold
4
– – ﹤0.01% 772
2024
Q3
$849 Hold
4
– – ﹤0.01% 834
2024
Q2
$1.12K Buy
+4
New +$952 ﹤0.01% 826

Other funds holding MDGL

Park Place Capital's MDGL Position: Q2 2026 in Review

Park Place Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 4 shares — an estimated $2.09K sold.

Park Place Capital first reported a position in MDGL in Q2 2024 and held it in 8 quarters. The position peaked at $2.33K in Q4 2025. 417 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Park Place Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Park Place Capital sold 4 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.09K.
  • Park Place Capital first reported a position in Madrigal Pharmaceuticals in Q2 2024 and held it in 8 quarters.
  • Park Place Capital's Madrigal Pharmaceuticals position peaked at $2.33K in Q4 2025.
  • 417 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.